JP Morgan downgrades Phreesia to Underweight from Neutral, sets price target at $13
JP Morgan downgraded Phreesia to Underweight from Neutral, setting a price target of $13. This is near the stock's Nov 10 close of $13.13.
How this was made

The 30-second read
Why it matters
Potential short‑term sell‑off; longer‑term outlook depends on upcoming earnings.
Market read
Analyst downgrade likely triggers immediate price decline for Phreesia.
What to watch
Recent contract wins or pipeline developments not mentioned could offset the downgrade.
Background
JP Morgan’s downgrade and $13 target are the only new facts presented.
Ticker impact
JP Morgan downgraded Phreesia to Underweight and set a $13 price target, a new analyst action affecting the stock.
downward pressure as investors price in the lower rating and target
Analyst downgrades historically move the stock lower, especially when accompanied by a price target at current levels.
Market effects
May weigh on other health‑tech firms as analysts reassess valuation multiples.
Limited to US-listed health‑tech sector.
Low; impact confined to niche market.
Counterpoint
Some investors may view the downgrade as an overreaction if the company’s fundamentals remain strong.
Key entities
- CompanyPhreesia
Healthcare technology firm providing patient intake solutions.
- AnalystJP Morgan
Investment bank issuing the downgrade.




